【歌礼制药-B(01672.HK):小分子口服GLP-1R激动剂ASC30美国13周IIa期研究完成首批肥胖或超重受试者

智通财经
Jul 03, 2025
【歌礼制药-B(01672.HK):小分子口服GLP-1R激动剂ASC30美国13周IIa期研究完成首批肥胖或超重受试者给药】智通财经APP讯,歌礼制药-B(01672.HK)发布公告,小分子口服GLP-1受体(GLP-1R)激动剂ASC30治疗肥胖症的美国13周IIa期研究(NCT07002905)已完成首批受试者给药,受试者为肥胖人群或伴有至少一种体重相关合并症的超重人群。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10